List of Excipients in Branded Drug INVELTYS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	INVELTYS	loteprednol etabonate	0065-9307	ANHYDROUS CITRIC ACID
Alcon Laboratories Inc	INVELTYS	loteprednol etabonate	0065-9307	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	INVELTYS	loteprednol etabonate	0065-9307	CITRIC ACID MONOHYDRATE
Alcon Laboratories Inc	INVELTYS	loteprednol etabonate	0065-9307	EDETATE DISODIUM

Inveltys Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Inveltys is a 1% loteprednol etabonate ophthalmic suspension developed by Kala Pharmaceuticals for postoperative ocular inflammation and pain. Its commercial differentiation depends less on the corticosteroid itself than on the formulation system: a high-strength suspension designed for ocular surface retention, spreading, redispersion, and twice-daily dosing. The principal commercial opportunities are generic development, excipient supply, formulation partnerships, preservative-free ophthalmic delivery, and lifecycle products based on the same delivery platform.

What is Inveltys and how is it formulated?

Inveltys contains loteprednol etabonate at 1% in an ophthalmic suspension. The FDA-approved regimen is one drop in the affected eye twice daily for two weeks following ocular surgery.[1]

The labeled inactive ingredients are:

Excipient	Probable formulation role
Boric acid	Buffering and tonicity control
Edetate disodium	Chelating agent and preservative-support excipient
Glycerin	Tonicity adjustment and hydration
Povidone	Wetting, dispersion, and viscosity control
Sodium citrate dihydrate	Buffering and pH control
Sodium chloride	Tonicity adjustment
Tyloxapol	Surfactant, wetting agent, and particle-dispersion aid
Water for injection	Aqueous vehicle
Hydrochloric acid and sodium hydroxide	pH adjustment

Inveltys is not a conventional solution. Loteprednol etabonate has limited aqueous solubility, so the product uses a suspension architecture. The commercial formulation must maintain a controlled particle population, prevent irreversible aggregation, provide adequate dose uniformity after shaking, and preserve ocular tolerability over the bottle’s in-use period.

The product is marketed in a multidose ophthalmic container. Its inactive-ingredient profile does not list benzalkonium chloride, which creates a commercial distinction from many preserved ophthalmic products and may support positioning for postoperative ocular use.

What excipient strategy supports Inveltys performance?

The Inveltys excipient system is designed around dispersion stability rather than simple solubilization.

How do tyloxapol and povidone function in the formulation?

Tyloxapol is a nonionic surfactant used to improve wetting of hydrophobic drug particles and reduce particle-particle adhesion. In a corticosteroid suspension, that function can improve redispersion and dose consistency after storage.

Povidone is a water-soluble polymer. Its likely contributions include particle wetting, suspension stabilization, and control of interfacial behavior. The selected grade and concentration can affect viscosity, sedimentation, drop formation, and ocular residence.

The combination creates a formulation platform with multiple control points:

• Particle wetting
• Sedimentation rate
• Redispersion after shaking
• Delivered dose per drop
• Surface spreading
• Ocular comfort
• Physical stability during storage

A generic developer cannot assume that substituting another surfactant or polymer will preserve performance. Small changes in molecular weight, concentration, or grade can alter particle growth, sediment compactness, drop size, and ocular tolerability.

Why are buffer and tonicity excipients commercially important?

Boric acid and sodium citrate dihydrate provide buffer capacity, while glycerin and sodium chloride support tonicity control. These components influence pH, osmolality, comfort, chemical stability, and compatibility with the container-closure system.

For ophthalmic suspensions, excipient selection must balance several competing parameters. Higher ionic strength can affect particle interactions. Buffer composition can influence drug degradation and surface charge. Tonicity changes can alter tolerability even when the product remains within a nominal ophthalmic range.

The formulation therefore has potential protection through composition, concentration ranges, manufacturing controls, particle attributes, and performance specifications rather than through the identity of a single excipient.

What is the role of edetate disodium?

Edetate disodium chelates trace metal ions that can catalyze degradation or promote instability. In ophthalmic products, it can also support antimicrobial control when used with an appropriate preservative system, although the Inveltys label does not identify benzalkonium chloride as an active preservative.

For competing products, edetate disodium can be commercially attractive because it is familiar to ophthalmic manufacturers and has an established regulatory history. Its use does not by itself reproduce the Inveltys formulation. The relevant issue is the total formulation and the resulting performance profile.

What delivery technology differentiates Inveltys?

Inveltys was developed using Kala’s mucus-penetrating particle technology. The company described the technology as using nanoparticles with a hydrophilic surface intended to reduce interaction with the mucus layer and improve distribution across the ocular surface.[2]

The technology is relevant commercially for three reasons:

1. It permits a 1% loteprednol etabonate suspension with twice-daily administration.
2. It creates a formulation-based differentiation from conventional loteprednol products.
3. It may support follow-on products using the same particle engineering and excipient platform.

The delivery platform is more difficult to copy than a standard aqueous suspension because performance depends on particle engineering, surface properties, excipient ratios, mixing order, homogenization, sterilization, and packaging.

What patents protect Inveltys and its formulation?

Inveltys protection is likely to involve several patent categories:

Protection category	Commercial relevance
Loteprednol etabonate composition	Protects the active ingredient or defined chemical form
Ophthalmic suspension composition	Covers excipient combinations, concentration ranges, and physical properties
Mucus-penetrating particles	Protects surface treatment, particle size, and delivery architecture
Method of treatment	Covers postoperative use, dosing frequency, or ocular indications
Manufacturing process	Covers particle preparation, blending, sterilization, and filling
Container-closure system	May protect multidose delivery and product stability

The most important competitive question is whether an ANDA applicant can design around formulation and delivery claims while demonstrating pharmaceutical equivalence. A generic product may avoid literal infringement by changing the polymer, surfactant, particle-size distribution, or manufacturing process. That design-around can increase development risk because the changed excipients may affect bioequivalence, stability, and ocular tolerability.

The current FDA Orange Book should be used to determine listed patents, use codes, and pediatric exclusivity for the relevant NDA.[3] The label and approval history establish the regulatory product profile, but they do not by themselves establish the full scope or enforceability of the patent estate.

When does Inveltys lose exclusivity?

Inveltys received FDA approval in 2018 under NDA 208571.[1] FDA exclusivity and patent protection are separate.

Regulatory exclusivity

A new chemical entity exclusivity period does not generally apply to Inveltys because loteprednol etabonate was previously approved in other products. The product’s commercial protection therefore depends mainly on patents, listed methods of use, formulation claims, and any applicable regulatory protections.

Patent exclusivity

Patent expiry dates depend on the specific patents listed for the NDA, terminal disclaimers, patent-term adjustment, patent-term extension, and any litigation outcome. A generic launch date cannot be determined from the approval date alone.

For commercial planning, the relevant timeline is:

Event	Strategic impact
NDA approval in 2018	Established FDA reference product
Orange Book patent listing	Determines potential ANDA certification obligations
Paragraph IV filing	Creates litigation and 30-month-stay risk
Patent litigation or settlement	May define an earlier authorized or at-risk launch
Patent expiration or invalidation	Removes the principal legal barrier to generic entry
First ANDA approval	May create limited first-filer commercial advantage if applicable

What is the Orange Book status of Inveltys?

Inveltys is an FDA-approved prescription ophthalmic product under NDA 208571.[1] Orange Book analysis should focus on:

• Listed patents for loteprednol etabonate ophthalmic suspension
• Method-of-use codes for postoperative inflammation and pain
• Whether patents cover the formulation, delivery technology, or both
• Expiration dates after patent-term adjustments
• Any patent delisting requests or court decisions
• First-approved ANDAs and Paragraph IV certifications

A listed method-of-use patent may be less commercially restrictive than a formulation patent if the generic applicant can use a proper carve-out strategy. A formulation patent is more significant because it can affect the product even when the applicant seeks approval for the same active ingredient and indication.

Which companies are challenging Inveltys?

The relevant competitive group includes:

• Generic ophthalmic manufacturers developing loteprednol products
• Companies with corticosteroid suspension platforms
• Ophthalmic drug-delivery companies using nanoparticles or surface-engineered particles
• Manufacturers developing postoperative anti-inflammatory combinations
• Suppliers offering alternative surfactants, polymers, and preservative-free multidose packaging

A public Paragraph IV challenge must be assessed through FDA ANDA records, Orange Book certifications, district court complaints, and Patent Trial and Appeal Board filings. A competitor’s presence in the loteprednol market does not establish a challenge to Inveltys specifically.

How does Inveltys compare with competing ophthalmic corticosteroids?

Product	Active ingredient	Strength	Dosage form	Typical dosing profile	Formulation distinction
Inveltys	Loteprednol etabonate	1%	Suspension	Twice daily for two weeks	Mucus-penetrating particle platform
Lotemax suspension	Loteprednol etabonate	0.5%	Suspension	More frequent administration historically	Conventional loteprednol suspension
Lotemax gel	Loteprednol etabonate	0.5%	Gel	Varies by indication	Gel vehicle
Durezol	Difluprednate	0.05%	Emulsion	Commonly four times daily initially	Emulsion-based corticosteroid
Pred Forte	Prednisolone acetate	1%	Suspension	Commonly frequent initial dosing	Established corticosteroid suspension

Inveltys competes through dosing convenience and formulation performance rather than through a new active ingredient. Durezol competes on potency and emulsion delivery. Pred Forte competes on price, physician familiarity, and generic availability. Lotemax products are the closest active-ingredient comparators but may not reproduce the same particle-engineering profile.

What generic entry risks exist for Inveltys?

The largest risk is a formulation-specific ANDA that matches the reference product sufficiently for FDA approval while avoiding asserted patent claims.

Key development barriers include:

• Demonstrating equivalent active-ingredient strength
• Matching particle-size distribution
• Controlling polymorphic form and crystallinity
• Demonstrating redispersion and dose uniformity
• Matching viscosity, pH, osmolality, and drop size
• Establishing comparable in vitro release
• Proving container-closure compatibility
• Maintaining sterility and microbiological quality
• Managing ocular irritation from substitute surfactants or polymers

A conventional loteprednol suspension may be easier to manufacture but may not be therapeutically or regulatorily equivalent to Inveltys. Conversely, a close formulation copy may face greater patent risk.

A 505(b)(2) strategy could support a modified loteprednol formulation, different dosage form, or different dosing regimen. It would not automatically eliminate patent risk and could require clinical or comparative pharmacology data.

What excipient opportunities exist for suppliers?

Surfactants and wetting agents

Tyloxapol supply, pharmaceutical-grade documentation, impurity control, and reliable batch-to-batch performance are direct commercial opportunities. Alternative nonionic surfactants could support design-around programs, but each substitute requires evaluation for ocular tolerability and suspension behavior.

Polymeric stabilizers

Povidone suppliers can compete through controlled molecular-weight grades, low-peroxide specifications, ophthalmic quality systems, and formulation support. Other polymers may offer opportunities in viscosity control or particle stabilization, but substitution creates a higher development burden.

Preservative-free multidose packaging

Packaging companies can target systems that limit microbial ingress without relying on benzalkonium chloride. This is relevant for postoperative ophthalmic products and chronic-use ocular products where preservative exposure is a commercial concern.

Particle engineering and contract development

The strongest opportunity is not a commodity excipient sale. It is integrated development covering:

• Nanoparticle production
• Surface modification
• Sterile processing
• Suspension stabilization
• Filling and packaging
• Analytical characterization
• In vitro release testing

Companies with proprietary particle-engineering methods can offer a differentiated route to follow-on products and reformulations.

What lifecycle opportunities exist for Inveltys?

Potential lifecycle products include:

• Preservative-free single-dose units
• Lower-volume or higher-concentration dosing
• Combination products with an antibiotic
• Products for anterior-segment inflammation beyond postoperative use
• Formulations optimized for cataract, corneal, or refractive surgery
• Extended-residence formulations with less frequent administration
• Pediatric or low-irritation presentations
• Alternative multidose delivery systems

The commercial value of these products depends on whether they create a clinically meaningful benefit and secure independent formulation, method-of-use, or device protection.

What is the revenue exposure and commercial outlook?

Inveltys revenue is exposed to three factors:

1. The size of the postoperative ophthalmic corticosteroid market.
2. The price premium supported by twice-daily dosing and delivery technology.
3. The timing and economics of generic entry.

Before generic competition, the product can command a premium over conventional loteprednol suspensions if surgeons and payers accept the convenience and formulation benefits. After generic entry, pricing pressure will depend on whether the generic matches the branded product closely, whether multiple manufacturers enter, and whether the reference sponsor retains share through contracts or line extensions.

The most defensible commercial assets are the formulation know-how, analytical methods, manufacturing process, and packaging system. Individual excipients such as glycerin, sodium chloride, or boric acid are weak standalone barriers. Their value comes from the controlled combination and its demonstrated performance.

Key Takeaways

• Inveltys is a 1% loteprednol etabonate ophthalmic suspension approved for postoperative inflammation and pain.
• Its excipient strategy centers on suspension stability, wetting, redispersion, tonicity, buffering, and ocular tolerability.
• Tyloxapol and povidone are important formulation components because they support particle dispersion and physical stability.
• The product’s mucus-penetrating particle platform creates greater formulation complexity than a conventional loteprednol suspension.
• Generic developers face technical barriers involving particle attributes, dose uniformity, release, stability, and ocular tolerability.
• The strongest commercial opportunities are formulation partnerships, pharmaceutical-grade excipients, sterile particle engineering, preservative-free packaging, and lifecycle products.
• Patent and generic-entry conclusions require review of the current Orange Book listings, use codes, certifications, litigation records, and settlement terms.

FAQs

Can a generic use different excipients from Inveltys?

Yes. An ANDA applicant may use different excipients if it satisfies FDA equivalence requirements and does not infringe enforceable patent claims. In ophthalmic suspensions, excipient changes can affect particle size, redispersion, dose uniformity, and tolerability.

Is Inveltys a solution or a suspension?

Inveltys is an ophthalmic suspension. The active ingredient is dispersed rather than fully dissolved in the aqueous vehicle.

Does Inveltys contain benzalkonium chloride?

Benzalkonium chloride is not listed among the inactive ingredients in the FDA prescribing information cited here.[1]

Is Inveltys protected by a new active-ingredient exclusivity period?

The product contains loteprednol etabonate, an active ingredient previously used in approved ophthalmic products. Its commercial protection is therefore expected to rely primarily on patents, formulation technology, method-of-use protection, and brand positioning.

Which excipient is most important to reproduce Inveltys performance?

No single excipient determines equivalence. Tyloxapol, povidone, particle engineering, manufacturing conditions, and the full buffer-tonicity system operate together. Replacing one component can change the performance of the entire suspension.

References

1. U.S. Food and Drug Administration. (2018). Inveltys (loteprednol etabonate ophthalmic suspension) prescribing information. NDA 208571.
2. Kala Pharmaceuticals, Inc. (2018). Inveltys: FDA approval and mucus-penetrating particle technology materials.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.